Today: 4 March 2026
Subscribe

Shan Ahmed Khan

As a journalist focused on finance and the stock market, he delivers fast, reliable, and easy-to-understand coverage of market news.

Lazard, Inc. (LAZ) Stock on 8 December 2025: Q3 Beat, Strategic Expansion and a Sharp Sell‑Off – What It All Means for Investors

Lazard, Inc. (LAZ) Stock on 8 December 2025: Q3 Beat, Strategic Expansion and a Sharp Sell‑Off – What It All Means for Investors

Lazard shares closed at $50.90 on December 8, down 7% from the previous session on light volume. The drop followed record adjusted revenue and strong advisory and asset management results in Q3, despite a 5% year-over-year decline in GAAP net revenue to $748 million. Adjusted EPS for the quarter rose 47% to $0.56, beating forecasts. Assets under management reached $265 billion, up 17% year-to-date.
8 December 2025
·
Life360 (ASX:360, Nasdaq:LIF) Stock on 8 December 2025: Q3 Beat, Nativo Deal, Sell‑Off and 2026 Forecasts

Life360 (ASX:360, Nasdaq:LIF) Stock on 8 December 2025: Q3 Beat, Nativo Deal, Sell‑Off and 2026 Forecasts

Life360 shares closed at A$37.83 on the ASX, down 3.84% and among the index’s biggest losers on 8 December, despite reporting record Q3 results and a major ad-tech acquisition. The Nasdaq line traded around US$73.18, with intraday swings between US$71.90 and US$78.01. Technical models project further downside, labeling the stock a “sell candidate” despite recent growth.
8 December 2025
··
Fluence Energy (FLNC) Stock Today: Downgrades Hit High-Flying Battery Storage Play – Latest News, Price Targets and Forecasts

Fluence Energy (FLNC) Stock Today: Downgrades Hit High-Flying Battery Storage Play – Latest News, Price Targets and Forecasts

Fluence Energy shares fell about 7–8% intraday on December 8 after Mizuho and Johnson Rice downgraded the stock, citing valuation and execution risks. The drop followed a sharp rally, with the stock still up over 30% year-to-date and trading near $22. The company reported $2.3 billion in fiscal 2025 revenue and announced a new UK battery project milestone. Wall Street consensus targets imply significant downside from current levels.
8 December 2025
··
Marvell Technology (MRVL) Stock Tumbles on Amazon and Microsoft Fears as AI Growth Story Gets Re‑Priced

Marvell Technology (MRVL) Stock Tumbles on Amazon and Microsoft Fears as AI Growth Story Gets Re‑Priced

Marvell Technology shares fell as much as 10% intraday on December 8 after Benchmark downgraded the stock, citing likely losses of Amazon’s Trainium 3 and 4 chip designs and concerns Microsoft could shift custom silicon work to Broadcom. The stock closed about 7% lower at $92.61. Zacks, meanwhile, upgraded Marvell to “Strong Buy” the same day, citing rising earnings estimates.
8 December 2025
···
Warby Parker (WRBY) Stock Soars on Google AI Glasses Timeline: Price Action, Earnings and 2026 Forecasts as of December 8, 2025

Warby Parker (WRBY) Stock Soars on Google AI Glasses Timeline: Price Action, Earnings and 2026 Forecasts as of December 8, 2025

Warby Parker shares surged nearly 15% to $21.51 on December 8 after new disclosures confirmed a 2026 launch of AI-powered smart glasses with Google under the Android XR platform. Trading volume spiked above average, pushing the stock about 58% above its 52-week low. Google has committed up to $150 million to the partnership. Warby Parker’s year-to-date stock performance remains down 26% despite the rally.
8 December 2025
··
Arrowhead Pharmaceuticals (ARWR) Soars to Fresh Highs on Alzheimer’s Trial and FDA Breakthrough Wins

Arrowhead Pharmaceuticals (ARWR) Soars to Fresh Highs on Alzheimer’s Trial and FDA Breakthrough Wins

Arrowhead Pharmaceuticals shares jumped 14–15% intraday on 8 December 2025, reaching a 52-week high near $69 after dosing the first subjects in its Alzheimer’s trial ARO-MAPT. The stock has returned about 270% year-to-date, with a market cap around $9–9.6 billion. The Phase 1/2a trial targets tau protein using Arrowhead’s RNAi platform. Liquidity ratios stand near 4.8, with beta between 1.3 and 1.5.
8 December 2025
·
Nurix Therapeutics (NRIX) Stock Soars on ASH 2025 Trial Data: Latest News, Analyst Forecasts and Outlook as of December 8, 2025

Nurix Therapeutics (NRIX) Stock Soars on ASH 2025 Trial Data: Latest News, Analyst Forecasts and Outlook as of December 8, 2025

Nurix Therapeutics shares jumped about 20% to $21.70 intraday on December 8, 2025, after new Phase 1 data for its BTK degrader bexobrutideg (NX-5948) in blood cancers was presented at the ASH Annual Meeting. The company reported an 83% response rate in relapsed/refractory CLL/SLL patients and scheduled a webcast for the evening. Volume was well above normal, with shares trading near a 52-week high.
8 December 2025
··
Carvana (CVNA) Soars on S&P 500 Inclusion: Latest News, Stock Forecast and Analysis as of December 8, 2025

Carvana (CVNA) Soars on S&P 500 Inclusion: Latest News, Stock Forecast and Analysis as of December 8, 2025

Carvana shares jumped about 14% to $454 on December 8 after S&P Dow Jones Indices said the company will join the S&P 500 on December 22. The stock is up over 115% in 2025 and has surged more than 8,000% since 2022 lows. Carvana’s market value now stands near $87 billion, surpassing Ford and GM. Index funds are expected to buy shares ahead of the inclusion.
8 December 2025
··
Kymera Therapeutics (KYMR) Stock Soars on KT‑621 Eczema Data: What December 8, 2025 Means for Investors

Kymera Therapeutics (KYMR) Stock Soars on KT‑621 Eczema Data: What December 8, 2025 Means for Investors

Kymera Therapeutics shares jumped nearly 50% Monday, closing near $96 after hitting an intraday high above $100, following strong Phase 1b results for its oral STAT6 degrader KT‑621 in atopic dermatitis. The trial showed about 98% median STAT6 degradation in blood and 94% in skin lesions. Trading volume was far above normal. Stifel raised its price target as the stock marked a new 52-week high.
8 December 2025
··
Wave Life Sciences (WVE) Stock Explodes on Obesity Drug Breakthrough – What the New Data and Wall Street Forecasts Signal

Wave Life Sciences (WVE) Stock Explodes on Obesity Drug Breakthrough – What the New Data and Wall Street Forecasts Signal

Wave Life Sciences shares soared as much as 140% Monday after reporting positive interim Phase 1 data for its obesity drug WVE-007. The stock hit $17–18 intraday on record volume topping 100 million shares, up from Friday’s $7.49 close. The trial showed a 9.4% drop in visceral fat and a 3.2% gain in lean mass at three months. Wave’s market value rose to about $2.5–3.0 billion.
8 December 2025
·
Confluent (CFLT) Soars on IBM’s $11 Billion Takeover: Deal Terms, Stock Outlook and Analyst Forecasts After December 8, 2025 Rally

Confluent (CFLT) Soars on IBM’s $11 Billion Takeover: Deal Terms, Stock Outlook and Analyst Forecasts After December 8, 2025 Rally

IBM will acquire Confluent for $31 per share in cash, valuing the company at about $11 billion. Confluent stock jumped nearly 29% on December 8, trading close to the buyout price after the deal was announced. Both boards approved the agreement, with major shareholders backing the transaction. Closing is expected by mid-2026, pending shareholder and regulatory approval.
8 December 2025
···
Banco Bradesco (BBD) Stock on December 8, 2025: Is the Post‑Earnings Sell‑Off a Buying Opportunity?

Banco Bradesco (BBD) Stock on December 8, 2025: Is the Post‑Earnings Sell‑Off a Buying Opportunity?

Banco Bradesco ADRs traded near $3.35 on December 8, 2025, recovering slightly after a 9% drop on December 5. Q3 net income rose 18.8% year-on-year to R$6.2 billion, but earnings per share missed estimates, triggering the selloff. Hedge funds cut stakes in Q2 while Fisher Asset Management raised its position. Analysts maintain a consensus “Buy” rating with 12-month targets between $2.40 and $3.72.
8 December 2025
··
Spirit AeroSystems (SPR) Stock on December 8, 2025: Boeing Takeover, NYSE Delisting and What Shareholders Get

Spirit AeroSystems (SPR) Stock on December 8, 2025: Boeing Takeover, NYSE Delisting and What Shareholders Get

Boeing completed its acquisition of Spirit AeroSystems on December 8, 2025, halting SPR trading and starting the NYSE delisting process. Each Spirit share will convert into 0.1955 Boeing shares. The deal values Spirit at about $4.7 billion in equity, or $8.3 billion including debt. Airbus will take over key Spirit sites and receive $439 million in compensation.
8 December 2025
···
Rivian Stock on December 8, 2025: Downgrade, Recall and R2 Hopes – What RIVN Investors Need to Know

Rivian Stock on December 8, 2025: Downgrade, Recall and R2 Hopes – What RIVN Investors Need to Know

Rivian shares fell 3–5% Monday to about $17.30 after Morgan Stanley downgraded the stock to Underweight and kept a $12 target. The move follows a recall of nearly 35,000 delivery vans and concerns over Rivian’s upcoming R2 SUV amid slowing EV demand. The stock remains up about 38–45% over the past year but is still down roughly 90% from its 2021 peak.
8 December 2025
·
UiPath (PATH) Stock Soars After First GAAP Profit: Can the AI Automation Rally Last? – December 8, 2025

UiPath (PATH) Stock Soars After First GAAP Profit: Can the AI Automation Rally Last? – December 8, 2025

UiPath shares hit new 52-week highs, closing at $19.12 on Dec. 8, 2025, after posting its first GAAP-profitable quarter and raising guidance. The stock has surged about 30% in the past month and over 50% in the last year, outpacing the S&P 500. Trading volume neared 19 million shares. Most analysts’ price targets remain below current levels.
8 December 2025
··
Structure Therapeutics (GPCR) Stock Soars on Obesity Pill Data: Latest News, Analyst Forecasts and 2026 Outlook (December 8, 2025)

Structure Therapeutics (GPCR) Stock Soars on Obesity Pill Data: Latest News, Analyst Forecasts and 2026 Outlook (December 8, 2025)

Structure Therapeutics shares surged 101% to $69.46 on December 8 after reporting positive Phase 2b data for aleniglipron, its oral GLP-1 agonist for obesity. Patients on 120 mg lost 12.1% of body weight at 36 weeks versus 0.8% for placebo. The company held $799 million in cash as of September 30.
8 December 2025
···
Bitcoin Nears $92K as Fed Rate-Cut Bets and XRP ETF Boom Lift Crypto – BTC, ETH, XRP and Solana Price Outlook for December 8, 2025

Bitcoin Nears $92K as Fed Rate-Cut Bets and XRP ETF Boom Lift Crypto – BTC, ETH, XRP and Solana Price Outlook for December 8, 2025

The total crypto market cap rose 2.2% to $3.2 trillion on Monday, December 8, 2025, as Bitcoin traded near $91,500 and Ethereum hovered around $3,130. Traders cited Federal Reserve rate-cut expectations and strong inflows into crypto ETFs. XRP held above $2.00 with U.S. spot ETFs nearing $1 billion AUM. Solana climbed to the mid-$130s amid continued ETF inflows.
8 December 2025
··
1 … 503 504 505 506 507 … 584
Go toTop